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Abstract
The risk factors for and clinical features of bloodstream infection with uncommon Candida spp. (species other than C. albicans,
C. glabrata, C. parapsilosis, C. tropicals and C. krusei) are incompletely deﬁned. To identify clinical variables associated with these spe-
cies that might guide management, 57 cases of candidaemia resulting from uncommon Candida spp. were analysed in comparison
with 517 episodes of Candida albicans candidaemia (2001–2004). Infection with uncommon Candida spp. (5.3% of candidaemia cases),
as compared with C. albicans candidaemia, was signiﬁcantly more likely to be outpatient-acquired than inpatient-acquired (15 of 57
vs. 65 of 517 episodes, p 0.01). Prior exposure to ﬂuconazole was uncommon (n = 1). Candida dubliniensis was the commonest
species (n = 22, 39%), followed by Candida guilliermondii (n = 11, 19%) and Candida lusitaniae (n = 7, 12%). C. dubliniensis candidaemia
was independently associated with recent intravenous drug use (p 0.01) and chronic liver disease (p 0.03), and infection with spe-
cies other than C. dubliniensis was independently associated with age <65 years (p 0.02), male sex (p 0.03) and human immunodeﬁ-
ciency virus infection (p 0.05). Presence of sepsis at diagnosis and crude 30-day mortality rates were similar for C. dubliniensis-
related, non-C. dubliniensis-related and C. albicans-related candidaemia. Haematological malignancy was the commonest predisposing
factor in C. guilliermondii (n = 3, 27%) and C. lusitaniae (n = 3, 43%) candidaemia. The 30-day mortality rate of C. lusitaniae candida-
emia was higher than the overall death rate for all uncommon Candida spp. (42.9% vs. 25%, p not signiﬁcant). All isolates were
susceptible to amphotericin B, voriconazole, posaconazole, and caspofungin; ﬁve strains (9%) had ﬂuconazole MIC values of
16–32 mg/L. Candidaemia due to uncommon Candida spp. is emerging among hospital outpatients; certain clinical variables may
assist in recognition of this entity.
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Introduction
Bloodstream infection with Candida spp. (candidaemia) is
associated with signiﬁcant morbidity [1–3]. Whereas the
epidemiological, clinical and microbiological features of candi-
daemia due to Candida albicans and the most common non-
albicans Candida spp. (Candida parapsilosis, Candida glabrata,
Candida tropicalis, and Candida krusei) are well deﬁned
[1,4–9], relatively little is known about other or less fre-
quently encountered non-albicans Candida spp. [10–13].
Given that candidaemia due to such uncommon Candida spp.
appears to be increasing, and that certain species, e.g. Can-
dida dubliniensis and Candida guilliermondii, have been reported
to be less susceptible or resistant to antifungal agents
[10,14–16], local epidemiological trends have important
implications for clinical management.
Most epidemiological surveys of uncommon Candida spp.
have been limited to single institutions or speciﬁc patient
populations, and have focused on only one pathogen
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[11–14], which may not be broadly representative. The epi-
demiological, clinical and antifungal susceptibility data associ-
ated with candidaemia due to uncommon Candida spp. were
therefore analysed during a 3-year prospective survey in
Australia [5]. Clinical features or risk factors that discrimi-
nate among fungaemia caused by these species and those
due to C. albicans, the commonest cause of candidaemia,
including that in Australia [4–7], could guide selection of anti-
fungal therapy pending species conﬁrmation. As C. dubliniensis
shares many phenotypic and virulence characteristics with
C. albicans, and, indeed, may be misidentiﬁed as C. albicans
[17,18], the clinical and laboratory features of C. dubliniensis
candidaemia were compared with those of C. albicans candi-
daemia. To better understand the pathogenic potential of
other uncommon Candida spp. (i.e. those other than C. dublini-
ensis), the predisposing factors for candidaemia due to these
species were also examined.
Materials and Methods
Study design
Prospective laboratory-based surveillance of all episodes of
candidaemia within Australia was undertaken during the per-
iod August 2001 to July 2004, as described elsewhere [5]. Clin-
ical information concerning each episode was collected on
day 5 and day 30 after the ﬁrst isolation of Candida from blood,
and included: demographic data, healthcare setting, risk factors
within the preceding 30 days, major comorbidities, clinical
features including sepsis [19], complications of candidaemia,
treatment, and clinical outcome 30 days after diagnosis.
Deﬁnitions
Candidaemia refers to the incident isolation of Candida spp.
from blood during the study period. The term ‘uncommon
Candida spp.’ (UCS) encompasses species other than C. albi-
cans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei.
Relapses were deﬁned as recurrent positive blood cultures
within 30 days of the ﬁrst positive culture after an initial clin-
ical and microbiological response. Episodes were considered
to be inpatient healthcare-associated if candidaemia was
diagnosed ‡48 h after hospital admission and patients had
no clinical manifestations on admission [20]. Outpatient
healthcare-associated cases were deﬁned as those occurring
<48 h after admission and associated with an indwelling
medical device, surgical procedure, or chemotherapy-related
neutropenia (<1 · 109 cells/L). Community-acquired infec-
tions were those in outpatients without such healthcare-
related risk factors. Attributable mortality was judged by
treating physicians as death that occurred in the presence of
ongoing clinical manifestations of candidaemia. Endocarditis
was classiﬁed according to modiﬁed Duke criteria [21].
Microbiological methods
Candida organisms were speciated by participating laborato-
ries using standard phenotypic methods [22], and forwarded
to a reference laboratory for species conﬁrmation [23] and
for antifungal susceptibility testing using CLSI M27-A2 broth
microdilution methodology [24]. MICs were read at 48 h of
incubation; breakpoints for susceptibility were adopted
according to CLSI methodology [24]. Species identity of all
UCS isolates was also determined by PCR ﬁngerprinting as
previously described [25].
Data analysis
Clinical data were analysed using SPSS version 10.0.7 (SPSS
Inc., Chicago, IL, USA). Variables associated with C. dubliniensis
candidaemia and with non-C. dubliniensis UCS bloodstream
infection were each compared with those associated with
C. albicans infection. Univariate analyses were performed
using Student’s t-test or non-parametric tests as appropriate
(for continuous variables) or the chi-square or Fisher’s exact
tests (for categorical variables). p-Values <0.05 were signiﬁ-
cant. Multivariate logistic regression analyses were
performed using the backwards selection method to identify
risk factors for candidaemia due to one or more UCS after
including all plausible variables and those with an unadjusted
association of p <0.1 using univariate analysis.
Results
Patient demographics
Over the 3-year period, 57 episodes of UCS-associated can-
didaemia in 57 patients were reported (5.3% of candidaemia
cases during this time). Demographic data were available for
54 (95%) episodes, and healthcare setting and clinical data
were available for 51 (90%) cases. These data were
compared with those reported for 517 cases of candidaemia
associated with C. albicans.
Two-thirds (n = 36) of patients were males, and the median
age was 45 years (interquartile range, 28–58 years). Adults
aged 15–64 years accounted for 80% of cases; adults aged
‡65 years, children aged 2 months to 14 years and neonates
aged £1 month accounted for 7%, 11%, and 2%, respectively.
Candida spp.
Eleven UCS were identiﬁed (Table 1); C. dubliniensis was the
most common (39% of UCS episodes), followed by C. guillier-
mondii (19%), and Candida lusitaniae (12%). Two episodes
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involved mixed Candida spp. (C. dubliniensis/C. glabrata and
C. dubliniensis/C. albicans) and were included in the ‘C. dublini-
ensis group’ for analyses.
Comparison of C. dubliniensis-related and C. albicans-related
candidaemia
Twenty-two episodes of C. dubliniensis candidaemia were
reported. The setting for acquisition of the infection included
inpatient healthcare (85%), outpatient healthcare (5%), and the
community (10%), similar to the acquisition settings for
C. albicans candidaemia (Table 2). Predisposing factors for
C. dubliniensis infection were also broadly similar to those
reported for C. albicans (Table 2). According to multivariate
analysis, patients with C. dubliniensis candidaemia were signiﬁ-
cantly more likely to have been current/recent intravenous
drug users (p 0.01) and to have chronic liver disease (p 0.03;
Table 2). Although a greater proportion of patients were aged
<65 years (90% vs. 65.2% for C. albicans candidaemia), younger
age (<65 years) was not independently associated with
C. dubliniensis infection. Manifestations of sepsis, 30-day crude
mortality and length of hospital stay were similar in C. dublinien-
sis-related and C. albicans-related candidaemia (Table 3).
TABLE 1. Uncommon Candida spp. causing candidaemia,
Australia 2002–2004
Candida spp. No. (%)
Candida dubliniensisa 22 (39)
Candida guilliermondii 11 (19)
Candida lusitaniae 7 (12)
Candida kefyr 5 (9)
Candida rugosa 3 (5)
Candida pelliculosa 3 (5)
Candida famata 2 (4)
Candida colliculosa 1 (2)
Candida lambica 1 (2)
Candida lipolytica 1 (2)
Candida sake 1 (2)
All species 57 (100)
aTwo episodes of C. dubliniensis candidaemia involved >1 Candida sp. (one
episode of C. dubliniensis/C. glabrata and on e of C. dubliniensis/C. albicans).









(n = 35 episodes) pc
C. albicans
(n = 517 episodes)
Univariate analysis
Age ‡65 years (4) 2/21 (10) 0.02 2/33 (6) <0.001 172/481 (35.8)
Male sex (36) 12/21 (57) 1.0 24/33 (73) 0.05 262/502 (52.2)
Adult ICU admission (5) 2/22 (10) 0.28 3/35 (9) 0.08 111/517 (21.5)
Acquisition of candidaemia
OHCA (9) 1/20 (5) 1.0 8/31 (26) 0.01 42/441 (9.5)
CA (6) 2/20 (10) 0.30 4/31 (13) 0.08 23/441 (5.2)
IHCA (36) 17/20 (85) 1.0 19/31 (61) 0.002 376/441 (85.3)
Underlying disease
Liver disease (6) 3/20 (15) 0.1 3/31 (10) 0.2 23/438 (5.3)
Haematological malignancy (14) 6/22 (27) 0.02 9/35 (26) 0.01 52/517 (10)
Non-haematological malignancy (7) 3/21 (14) 1.0 4/33 (12) 0.63 82/481 (17)
Diabetes (5) 2/22 (9) 0.76 3/35 (9) 0.60 68/517 (13.2)
Autologous HSCT (3) 1/20 (5) 0.24 2/31 (7) 0.07 5/438 (1.1)
Solid organ transplantation (2) 1/20 (5) 0.42 1/31 (3) 0.56 11/438 (2.5)
HIV (6) 1/20 (5) 0.13 2/31 (7) 0.02 2/438 (0.5)
Risk factors
Intravenous drug use (6) 3/19 (16) 0.02 3/28 (11) 0.05 11/428 (2.6)
Vascular access device (33) 15/19 (79) 0.76 18/27 (67) 0.07 352 (68.1)
Recent surgery (13) 7/19 (37) 0.48 6/28 (21) 0.01 204/428 (47.7)
Recent TPN (9) 3/19 (16) 0.09 6/28 (21) 0.11 160/429 (37.3)
Neutropenia (17) 7/19 (37) 0.01 10/29 (35) 0.01 60/434 (13.8)
Recent corticosteroid receipt (11) 7/19 (37) 0.45 4/28 (14) 0.13 124/427 (29)
Cytotoxic chemotherapy (14) 7/20 (35) 0.003 7/31 (23) 0.03 42/438 (8.1)
Systemic antifungal exposure (1) – – 1/29 (3) – 39/428 (9.6)
Recent antibiotic exposure (38) 15/19 (79) 0.25 23/29 (79) 0.12 383/429 (89.3)





Age £65 years – NS 11.1 (1.4–86) 0.02
Male sex – NS 3.0 (1.1–8.3) 0.03
Intravenous drug use 7.3 (1.5–34) 0.01 – NS
Liver disease 2.4 (0.6–8.8) 0.03 – NS
HIV infection – NS 9.0 (1.0–83) 0.05
CA, community-acquired; HIV, human immunodeﬁciency virus; HSCT, haematopoeitic stem cell transplantation; ICU, intensive-care unit; IHCA, inpatient healthcare-associ-
ated; NS, not signiﬁcant; OHCA, outpatient healthcare-associated; TPN, total parenteral nutrition.
aNo./total no. (%) for each category where the data were available, unless otherwise indicated.
bRefers to the total no. present in all episodes of bloodstream infection with uncommon Candida spp.
cComparisons using C. albicans candidaemia as reference category.
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Comparison of non-C. dubliniensis-related and
C. albicans-related candidaemia
Thirty-ﬁve cases of non-C. dubliniensis UCS infection
occurred during the study period. A signiﬁcantly greater pro-
portion of episodes were outpatient-acquired, as compared
with episodes of C. albicans candidaemia (39% vs. 15%,
p 0.002); furthermore, more than one-quarter of cases were
outpatient healthcare-associated (26% vs. 10%, p 0.01). As
compared with C. albicans candidaemia (Table 2), indepen-
dently signiﬁcant variables associated with non-C. dubliniensis
UCS were age <65 years (p 0.02), male sex (p 0.03), and
human immunodeﬁciency virus (HIV) infection (p 0.05).
A single patient (3%) had prior exposure to ﬂuconazole,
as compared to 39 of 517 (8%) patients with C. albicans candi-
daemia (p not signiﬁcant). Thirty-day mortality did not differ
from that associated with C. albicans candidaemia (Table 3).
Together, C. guilliermondii and C. lusitaniae accounted for
approximately one-half of non-C. dubliniensis UCS infections.
As in episodes of C. dubliniensis candidaemia, underlying
haematological malignancy (with attendant cytotoxic chemo-
therapy exposure and neutropenia) was the most frequent
predisposing factor, although both species were uncommon
in other patient groups. The 30-day crude mortality of C. lusi-
taniae candidaemia was higher than that of C. dubliniensis
(43% vs. 28%; Table 2). Other species of UCS included Can-
dida rugosa (n = 3), which caused candidaemia in patients
with haematological malignancy, with or without neutropenia.
Candida pelliculosa caused infection in patients with HIV infec-
tion (n = 2), recent surgery (n = 3), and intravenous drug
use (n = 1).
Outcome of candidaemia
Complications of UCS candidaemia were rare; one of 13
patients who underwent ophthalmological examination had
intra-ocular candidiasis and one of 44 examined by echocar-
diography had probable endocarditis. Both manifestations
were diagnosed within 30 days following the ﬁrst positive
blood culture. There were no relapses of candidaemia. The
TABLE 3. Clinical characteristics
and outcomes of Candida dublini-
ensis and non-C. dubliniensis
uncommon Candida spp.-related




(n = 22 episodes)
Non-C. dubliniensis
uncommon Candida




Clinical manifestations of sepsis, no. (%) 16/19 (84) 19/27 (70) 348/425 (81.9)
Ventilation on day 1, no. (%) 4/19 (21) 5/(19) 146/517 (34.3)
Length of stay (days) following candidaemia,
mean (±SD)
38.1 (±22.7) 32.9 (±39.5) 50.6 (±56)
Thirty-day crude mortality, no. (%) 5/18 (27.7) 6/26 (23) 123/422 (29.2)
SD, standard deviation.






















AMBb MIC50 0.06 0.25 0.06 0.5 – – –
MIC90 0.125 0.5 – – – – –
Range (no. tested) 0.06–0.25 0.06–0.5 0.03–0.125 0.25–1 0.5 (2) 0.125–0.25 0.25 (1)
5-FC MIC50 0.06 0.03 0.03 0.03 – – –
MIC90 0.125 0.125 – – – – –
Range (no. tested) 0.03–64 0.03–0.125 0.03 0.03–16 0.125–0.5 (2) 0.03–32 0.06 (1)
FLU MIC50 0.25 4 0.125 0.125 – – –
MIC90 1.0 16 – – – – –
Range (no. tested) 0.05–32 1–32 0.5–8 0.25–0.5 1–16 (2) 4 4 (1)
ITC MIC50 0.03 0.5 0.125 0.03 – – –
MIC90 0.125 1 – – – – –
Range (no. tested) 0.008–0.25 0.25–2 0.06–1 0.008–0.06 006–0.125 (2) 0.25 0.5 (1)
VOR MIC50 0.008 0.125 0.016 0.008 – – –
MIC90 0.016 0.25 – – – – –
Range (no. tested) 0.008–0.06 0.06–0.5 0.008–0.125 0.008–0016 0.008–0.06 (2) 0.06–0.125 0.125 (1)
POS MIC50 0.06 0.25 0.06 0.25 – – –
MIC90 0.125 0.5 – – – – –
Range (no. tested) 0.03–0.125 (10) 0.06–0.5 (7) 0.008–0.25 (5) 0.03–0.25 0.125 (2) 0.125–0.25 0.25 (1)
CAS MIC50 0.06 0.5 0.25 0.06 – – –
MIC90 0.25 0.5 – – – – –
Range (no. tested) 0.008–0.5 0.25–2 0.25–0.5 0.03–0.125 0.25–2 (2) 0.06–0.25 0.5 (1)
AMB, amphotericin B; CAS, caspofungin; FLU, ﬂuconazole; 5-FC, 5-ﬂucytosine; ITC, itraconazole; POS, posaconazole; VOR, voriconazole.
aRemaining isolates: one isolate each of Candida colliculosa, Candida lambica, Candida lipolytica, and Candida sake.
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crude 30-day mortality for all UCS was 25% (11 deaths in 44
episodes) and the attributable mortality was 11%. There
were no deaths among 12 patients with outpatient-acquired
infection, whereas 11 among 32 (34%) patients with inpatient
healthcare-associated infection died (p 0.02).
Antifungal susceptibility
MICs for UCS of seven antifungal agents are shown in
Table 4. Resistance was rare. However, ﬁve strains (three
C. guilliermondii and one each of C. rugosa and C. dubliniensis)
had susceptible-dose-dependent MIC values of ﬂuconazole
(MIC 16–32 mg/L): three of these were recovered from
patients who subsequently died. Seven C. guilliermondii iso-
lates and one isolate each of C. dublinenis, Candida colliculosa,
Candida famata and Candida lipolytica were susceptible-dose-
dependent to itraconazole (MIC 0.25–0.5 mg/L). All isolates
were susceptible to voriconazole (MIC £1 mg/L) and dem-
onstrated posaconazole MICs of £0.25 mg/L where tested.
C. lusitaniae isolates had low MICs of amphotericin B
(range 0.03–0.25 mg/L). Caspofungin demonstrated good
activity against all species; one isolate each of C. guilliermondii
and C. rugosa had MICs of 2 mg/L.
Discussion
The risk factors for, and clinical presentation of, infection
due to uncommon but emerging (non-C. albicans) Candida
species (UCS) [8,9,11–15] are incompletely deﬁned.
Although ‘uncommon’ in most clinical settings, these spe-
cies may pose therapeutic dilemmas in individual patients.
The clinical relevance of such pathogens relates primarily to
the association of a number of these species with antifungal
drug resistance, and with reportedly poorer clinical out-
comes [11,15,16,26]. This study has provided an overview of
the epidemiology of candidaemia with UCS and has identiﬁed
a number of clinical variables associated with the isolation of
these species that may guide selection of initial antifungal
therapy.
Only collaterally considered in other population-based
surveys of candidaemia, the proportion of cases where UCS
are isolated has ranged from 1.3% to 3% [7,27]. However,
two hospital-speciﬁc studies from Latin America reported
substantially higher rates of infection (11.7–18% of cases)
[28,29]. This variation is not readily explained, but may be
due to differences in case mix. In our cohort of unselected
patients, UCS caused 5.3% of candidaemia episodes. Impor-
tantly, these infections were not restricted to hospital inpa-
tients and, as compared with C. albicans candidaemia, were
signiﬁcantly more likely to be outpatient-acquired than
inpatient-acquired. Indeed, population-based surveillance thus
allowed us to identify nearly 30% of cases that would not
have been captured by nosocomial surveillance. This is rele-
vant to clinical practice, given the shift towards home-based
management of patients with risk factors for candidaemia,
and the overall emergence of candidaemia outside of hospi-
tals [5,30]. As no other surveys have examined the clinical
relevance of UCS in the general population, the generaliza-
tion of our ﬁndings requires conﬁrmation.
Established risk factors for candidaemia [1,2] were
evident among many of the patients in this study. As in
other studies of UCS [11–14], patients with haematological
malignancy were at particular risk; however, UCS were also
recovered from patients with chronic medical conditions,
including liver disease, diabetes mellitus, and HIV infection,
and from intravenous drug users. In addition, a number of
variables associated with isolation of UCS were identiﬁed;
age <65 years, male sex and HIV infection were indepen-
dent predisposing factors for infection with non-C. dublinien-
sis UCS, whereas chronic liver disease and intravenous drug
use were associated with C. dubliniensis candidaemia
(Table 2). Further studies of larger numbers of patients
with infections due to UCS are required to conﬁrm these
associations.
Previous attempts to identify unique risk factors for the
development of non-C. albicans candidaemia have necessarily
focused on the more ‘common’ species (e.g. C. glabrata),
with prior ﬂuconazole exposure, in particular, being reported
as a risk factor [9,31,32]. Data from the present study hint
that there may be differences in risk factors for candidaemia
due to UCS. UCS were isolated almost exclusively from
patients without prior antifungal exposure, suggesting that,
thus far, azole use has not played a major role in their selec-
tion. Patients aged <65 years were signiﬁcantly more likely
to develop candidaemia with UCS, whereas C. glabrata candi-
daemia has been associated with older age [33]. However,
interpretation of these data must take into consideration
species–species epidemiological differences within both ‘com-
mon’ and ‘uncommon’ non-C. albicans Candida pathogens
(this study) [1,11–14].
This study extends previous epidemiological data regard-
ing UCS. C. dubliniensis was the most common species,
causing 2% of candidaemia episodes [5], consistent with
previously reported rates (0.7–7%) [6,13,34]. However,
other studies have reported dominant species such as C. rug-
osa [29], C. pelliculosa [28], or C. guilliermondii [7,11,29].
Direct comparison of rates of isolation of speciﬁc species is
confounded by the differing tendencies of laboratories to
identify Candida to the species level. Nevertheless, the data
afﬁrm the results of smaller series, that C. dubliniensis
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causes candidaemia in patients with a range of clinical con-
ditions [13,34]. As C. dubliniensis possesses many of the vir-
ulence characteristics associated with C. albicans [17], it
may be expected to cause the same spectrum of disease;
indeed, the epidemiology of C. dubliniensis candidaemia is
more similar to that of C. albicans candidaemia than is the
epidemiology of non-C. dubliniensis spp. (Table 2). As noted
previously [11,12], immunocompromised patients with hae-
matological malignancy were at particular risk of C. lusitaniae
or C. guilliermondii candidaemia. C. lusitaniae infection has
also been reported to be associated with prior antifungal
treatment [12], but we were unable to conﬁrm whether
antifungal exposure selects for this species, due to insufﬁ-
cient patient numbers. Although only three cases of C. rug-
osa candidaemia were encountered in the present study,
this species is notable for its association with nosocomial
case clusters [14,29].
Importantly, candidaemia with UCS was not indicative of
more severe disease or of poorer outcome, as compared
with C. albicans candidaemia, although the mortality of C. lusi-
taniae infection was higher (p not signiﬁcant). This relatively
benign outcome contrasts with that reported elsewhere
[11,12,35]. However, deaths occurred only in hospitalized
inpatients, emphasizing the complexity of factors that
inﬂuence outcome [1,3].
Finally, in vitro resistance to azole agents was rare
among the present cohort of UCS isolates, although a
small number, including three C. guilliermondii strains, tested
susceptible-dose-dependent to ﬂuconazole. In contrast, oth-
ers have reported azole resistance rates of 10–15% among
C. guilliermondii strains [11,26]. Data from yet another sur-
vey caution against the use of azoles to treat C. rugosa
infections, as only 41% and 61% of strains were ﬂuconaz-
ole-susceptible and voriconazole-susceptible, respectively
[15]. In this study, voriconazole and posaconazole had
good activity against all species tested. The differences in
prevalence of resistance may reﬂect case mix or geograph-
ical differences, emphasizing the importance of understand-
ing local epidemiological factors. Although resistance to
amphotericin B among C. lusitaniae strains was not
detected, this species rapidly acquires resistance to ampho-
tericin B in vitro, and current opinion advises against its
use for the treatment of such infections [12].
The limitations of the study are recognized; the patient
cohort was small, and longitudinal data were not collected
beyond 30 days. Some authors recommend follow-up of
patients beyond 30 days to detect delayed complications
[2,36]. In one report, meningitis following C. dubliniensis
fungaemia developed 3 months after ‘cure’ of infection
[36].
In conclusion, UCS are emerging among hospital outpa-
tients. Certain clinical variables may enable recognition of
candidaemia caused by these species. Resistance to azole and
amphotericin B antifungal agents is uncommon, and clinical
outcomes at day 30 are similar to those for C. albicans candi-
daemia. Nevertheless, identiﬁcation of risk factors and identi-
ﬁcation of all Candida organisms at the species level from
blood are of value in understanding the pathogenesis of inva-
sive candidiasis.
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N. Gerns); Sullivan and Nicolaides Pathology (J. Botes, S. Che-
rian, J. Robson, R. Vohra); Townsville Hospital (R. Norton);
The Prince Charles Hospital (C. Coulter, G. O’Kane).
New South Wales: Albury Base Hospital (D. Robb); Concord
Hospital (T. Gottlieb); Douglass Hanly Moir Pathology
(I. Chambers); Gosford Hospital (D. DeWit); Grifﬁth
Hospital Base (M. Carroll); Hunter Area Pathology Service
(P. Dobson, J. Ferguson, S. Graves, L. Tierney); Liverpool
Hospital (F. Jozwiak, R. Munro, V. Tomasotos); Manning Base
Hospital (R. Pickles); Mayne Health (J. Holland); Narrabri
District Hospital (F. Groenwald); New Children’s Hospital
(K. Hale, M. Watson); Orange Base Hospital (R. Vaz); Prince
of Wales Hospital (R. Hardiman, C. Baleriola, S. Ryan); Royal
North Shore Hospital (R. Pritchard, K. Weeks); Royal Prince
Alfred Hospital (R. Benn); St George Hospital (R. Lawrence,
P. Taylor); St George Private Hospital (S. Lindstrom);
St Vincent’s Private and St Vincent’s Public Hospital (J. Hark-
ness, D. Marriott, Q. Nguyen); Sydney Children’s Hospital (P.
Palasanthrian); Sydney Adventist Hospital (R. Grant, R. McPet-
rie); Wagga Wagga Base Hospital (R. Johnson); Westmead
Hospital (S. Chen, C. Halliday, K. Maszewska, W. Meyer,
T. Sorrell); Wollongong Hospital (N. Dennis, P. Newton).
Victoria: Alfred Hospital (C. Franklin, O. Morrisey, M. Slavin,
D. Spelman, S. Wesselingh); Austin and Repatriation Hospital
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(B. Speed); Bendigo Health Care Group (J. Hellsten, B. Mayall,
J. Russell); Frankston Hospital (S. Broughton, I. Woolley);
Melbourne Pathology (S. Coloe); Melbourne Private Hospital
(A. Sherman); Monash Medical Centre (T. Korman); PathCare
Consulting Pathologists (S. Graves); Peter MacCallum Cancer
Institute (M. Slavin, M. Huysmans); Royal Melbourne Hospital
(M. Slavin, A. Sherman).
South Australia: Flinders Medical Centre (D. Gordon); Royal
Adelaide Hospital (K. Rowlands, D. Shaw); Women’s and
Children’s Hospital (D. Ellis, B. Ritchie, R. Handke).
Western Australia: Fremantle Hospital (M. Beaman, A.
Chiam, J. McCarthy); Royal Perth Hospital (C. Heath); Sir
Charles Gairdner Hospital (S. Altmann, I. Arthur, D. Speers).
Tasmania: Launceston General (E. Cox); Royal Hobart Hospi-
tal (L. Cooley, A. McGregor).
Northern Territory: Royal Darwin Hospital (B. Currie, G. Lum,
D. Fisher).
Australian Capital Territory: The Canberra Hospital (P. Colli-
gnon, J. Roberts, A. Watson).
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